Home/Filings/4/0001864159-25-000005
4//SEC Filing

Meyer Andrew Hollman 4

Accession 0001864159-25-000005

CIK 0001817713other

Filed

Nov 13, 7:00 PM ET

Accepted

Nov 14, 8:00 PM ET

Size

8.8 KB

Accession

0001864159-25-000005

Insider Transaction Report

Form 4
Period: 2025-11-14
Meyer Andrew Hollman
Chief Business Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2025-11-14$10.59/sh+3,333$35,29688,307 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2025-11-143,333118,101 total
    Exercise: $10.59Exp: 2031-05-13Common Stock (3,333 underlying)
  • Sale

    Common Stock

    2025-11-14$30.00/sh3,333$99,99084,974 total
Footnotes (3)
  • [F1]Includes 1 share acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on November 15, 2024 and 2,834 shares acquired under the Plan on May 15, 2025.
  • [F2]The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024.
  • [F3]Immediately exercisable.

Issuer

Janux Therapeutics, Inc.

CIK 0001817713

Entity typeother

Related Parties

1
  • filerCIK 0001864159

Filing Metadata

Form type
4
Filed
Nov 13, 7:00 PM ET
Accepted
Nov 14, 8:00 PM ET
Size
8.8 KB